HIV and COVID-19 Comorbidity: Current Evidence - International Journal of ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
International Journal of Science and Healthcare Research
Vol.5; Issue: 2; April-June 2020
Website: ijshr.com
Review Article ISSN: 2455-7587
HIV and COVID-19 Comorbidity: Current
Evidence
Adeniyi David Segun
Technical Officer - Directorate of Laboratory Services - APIN Public Health Initiatives, Jos, Nigeria.
ABSTRACT Key Words: COVID-19, SARS-CoV-2, HIV,
Comorbidity, PLWH
The spread of the COVID-19 has now crossed
all known human borders with so much 1. INTRODUCTION
virulence and defiance to the acclaimed When the first incidence cases of the
international efforts aimed at mitigating its Coronavirus Diseases 2019 (COVID-19)
impacts. The emergence of this disease in emerged at Wuhan China in early December
December 2019 at Wuhan in China has left the
2019, the world was still in a state of
world in tatters; with collapsed national
economies, massive loss of jobs and sources of slumber; not knowing the marauding impact
livelihoods, a redefining of social ethics and of what was coming. As tale bits of news
concourse, and a restructuring of the ethos that begins to filter into main stream media and
guide our national ways of life. The increased the internet about a novel strain of
risk of severe disease with COVID-19 is closely Coronavirus rampaging China from late
associated with advanced age (>50 years), male January 2020, the world became alert and
gender, hypertension, diabetes, Chronic suddenly woke up into a nightmare of epic
Obstructive Pulmonary Diseases, proportion. Social life and the ingrained
Cardiovascular diseases, and Cerebrovascular idea of personal liberty and freedom has not
diseases. People Living With HIV are most being the same ever since, and this is
prone to increased morbidity, and the advent of
coupled with the crumbling of the world
the COVID-19 has now created an additional
comorbid burden on the over 37.9 million economies, loss of jobs, and a monumental
PLWH globally. There is no known cure or toll on the mental health of individuals.
effective treatment for COVID-19 as at yet, but Medical Experts all over the world by
there are promising therapeutic alternatives. merely observing the virulence nature and
People Living With HIV stands a better chance the case fatality rate of this novel disease
of a positive disease outcome when infected knew what was coming, however, the WHO
with COVID-19 provided their viral load is held that this was not a pandemic until
suppressed, if they are on an active HIV March 11, 2020. [1] The COVID-19 has
Antiretroviral Therapy, if they have a high CD4 however being transmitted to at least 213
T-helper cells counts (>200 cells/µL), and countries ever since, leading to the complete
provided they have no underlying chronic
shutdown of cities, human social activities
diseases conditions. Some studies have shown
that a dysregulated immune response might be and entire nations. Bringing social and
responsible for conferring some level of economic activities to a standstill while still
protection against the SARS-CoV-2 virus marching on with the defiance of an all-
infection in HIV patients. Thus, the disease conquering master. Nevertheless, the world
outcome of People Living with HIV who are co- will overcome this common enemy with a
infected with the SARS-CoV-2 virus is no common resolve, cooperation and mutual
different from the prognostic outlook of any efforts.COVID-19 is a viral respiratory
averagely healthy individual infected with the disease that causes severe Pneumonia. As at
SARS-CoV-2 virus without any underlying June 12, 2020, over 7.5 million COVID-19
chronic health conditions.
International Journal of Science and Healthcare Research (www.ijshr.com) 349
Vol.5; Issue: 2; April-June 2020Adeniyi David Segun et.al. HIV and COVID-19 comorbidity: current evidence
cases have been reported globally with over disease outcome and increased case fatality
422 thousand deaths and over 3.5 million rate among COVID-19 patients with
recoveries. [2] Due to the rapid spread of this underlying chronic disease conditions like
disease and the very high mortality rate Hypertension, Diabetes, Cardiovascular
associated with it, it is imperative that the diseases, Cerebrovascular diseases, and
comorbidities and the associated risk factors Chronic Obstructive Pulmonary Diseases
that may predicate the clinical outcome of (COPDs). [3, 7-8, 10, 16] In the pooled analysis
this disease be clearly established as this of 1558 COVID-19 patients from 6 studies,
may help guide the clinical and palliative Wang, et al. [3] finds no correlation
management of this disease. Studies have associated with comorbidity risk among
shown that comorbidities in COVID-19 COVID-19 patients with malignancies, liver
patients may lead to poor prognosis. [3-4] diseases or renal diseases; instead, they find
Due to the novel nature of COVID- major risk factors associated with
19, many facts about the nature of this hypertension, diabetes, cardiovascular
disease are still emerging. Several studies to diseases, and COPDs. Diabetes Mellitus
establishing its risk factors, comorbidities, (DM) have been distinctively associated
possible choice of chemotherapy, and the with more severe COVID-19 case fatality
development of an appropriate vaccine and increased mortality rate. [17] In addition,
against the COVID-19 strain is still as older adults (>50 years) have been
ongoing. Due to the case fatality rate of this increasingly associated with poor prognosis
disease, it has been associated with several of COVID-19, DM can be presumed more
comorbidities that forms a cluster of chronic likely to be prevalent among the older
health conditions. [3, 5-10] HIV is a chronic population than among the younger
disease condition associated with population; this may partly explain the
immunosuppression, thus the emergence of underlying cause of the increased case
COVID-19 now create an additional burden fatality among the adult population. [17]
of disease for the over 37.9 million People Other studies have also shown a high
Living with HIV (PLWH) globally. [11] Case prevalence of Cardiovascular Diseases
series of COVID-19 infection in HIV among COVID-19 patients. [5-6, 8] Yang, et
patients have been reported from China, al. (2020) has also reported that the most
Europe, and the United States, [12-15] but thus common COVID-19 comorbidity associated
far, the disease progression and outcome in with increased mortality among COVID-19
this group of patients have not been non-surviving patients is cerebrovascular
different from those of HIV Negative diseases and Diabetes. [8]
individuals. [12-15] This review seeks to 3. HIV and COVID-19 Comorbidity:
establish the low risk associated with the Current Evidence
comorbidity of HIV and COVID-19 in light Due to the compromised immunity
of available evidence. of PLWH, such patients are most prone to
2. COVID-19 and Chronic Health morbidities. Thus with the advent of the
Conditions COVID-19 pandemic, the morbidity burden
The advent of the COVID-19 has let on PLWH has increased. Our current
loose a plethora of underlying chronic knowledge indicates that older adults (>50
health conditions in affected individuals. years), male gender, those with underlying
The comorbidity of this underlying chronic chronic diseases conditions and with
health conditions and COVID-19 has compromised immunity stands a greater
significantly increased the Odd Ratio (OR) chance of more severe COVID-19 infection
of affected patients having a poor COVID- prognostic outcome with increased fatality
19infection outcome. [9] Several meta- and mortality rates. Available data from
analytical studies on COVID-19 different studies have however excluded
comorbidities have revealed the poor PLWH without any other underlying
International Journal of Science and Healthcare Research (www.ijshr.com) 350
Vol.5; Issue: 2; April-June 2020Adeniyi David Segun et.al. HIV and COVID-19 comorbidity: current evidence
chronic health conditions from this high-risk efficacy at treating COVID-19. Such drugs
population, provided they are on ART with include the famed Hydroxychloroquine with
a reasonably high CD4 T-helper cells count or without Azithromycin, and Chloroquine,
(>200 cells/µL). [12] Studies have shown that which has not been well proven as at yet to
in PLWH, a dysregulated immune response be effective against the COVID-19 infection
to the SARS-CoV-2 infection leads to a in the face of other complicated adverse
delayed plasma antibody production against effects. [22] Other drugs undergoing trials
the COVID-19 virus and a lack of include the HIV drug Lopinavir/Ritonavir,
inflammatory changes with no clinical which has also been proven not to be
symptoms elicited after infection with the effective in the treatment of COVID-19.
virus. [18-19] According to a report by Joob Other promising drugs currently being
and Wiwanitkit (2020), PLWH who are not tested include the failed Ebola drug,
on HIV Antiretroviral Therapy (ART) are at Remdesivir and Famotidine which has so far
increased risk of developing a more severe shown possible signs of efficacy based on
form of the COVID-19. [13] However, the COVID-19 survival rate of clients on
PLWH who are currently on the standard these drugs as compared to those clients on
ART regimen and whose CD4 T-helper Placebo. [12,21] Several other efforts are
cells are >200 cells/µl without any being made at developing an active vaccine
underlying chronic diseases conditions will against the SARS-CoV-2 virus. Efforts are
have better prognostic outcome as also under way at identifying the specific
comparable to other averagely healthy antibodies produced against the SARS-
SARS-CoV-2 infected individuals without CoV-2 virus from the plasma of
any underlying chronic diseases conditions. convalescing or recovered COVID-19
[13]
Some researchers have presumed the patients. It should also be noted that PreP
possibility of the standard anti-HIV drugs treatments have not shown any effectiveness
being able to proffer a protective against COVID-19 recovery. [12]
mechanism against the SARS-CoV-2 5. HIV Services during the COVID-19
infection in PLWH. [13, 18] However, a large Pandemic
countrywide survey in China has shown that Due to the global shutdowns,
such standard anti-HIV drugs like lockdowns, social distancing, and the total
Lopinavir/Ritonavir though largely restriction of movements occasioned by the
publicized, as a possible wonder drug COVID-19 Pandemic, many of the gains
against the COVID-19, may not really be of made at mitigating the impacts of earlier
much benefit to COVID-19 patients. [20] pandemic diseases like HIV and
[23]
Thus at a time like this, it is imperative that Tuberculosis are now being eroded. The
we encourage PLWH to religiously adhere emergence of the COVID-19 pandemic now
to their ART regimens, ensuring their viral threatens the achievement of the UNAIDS
Load is suppressed, while also dispensing to 90:90:90 targets on HIV. The restrictions on
them prophylactics against Opportunistic movement have now hampered many
Infections (OIs). [12] HIV/AIDS clients from assessing ART and
4. COVID-19 Treatment clinic visits. [24] Many PLWH are now
As the race to finding a cure for the unable to get their needed Antiretroviral
COVID-19 intensifies, the WHO is leading (ARV) drugs refill as at when due as a result
the charge in a global effort aimed at of the restrictions on movement which is
harnessing a solid treatment data that could limited to only personnel on essential duties.
help proffer the way forward in the midst of In some countries with the rumored efficacy
this current global conundrum. [21] Several of Lopinavir/Ritonavir against the COVID-
possible drugs are currently undergoing 19 infection, there has been the steady
randomized control trials at different parts shortage of this HIV drug because of
of the world in a bid to assessing their hoarding by uninformed individuals. The
International Journal of Science and Healthcare Research (www.ijshr.com) 351
Vol.5; Issue: 2; April-June 2020Adeniyi David Segun et.al. HIV and COVID-19 comorbidity: current evidence
unavailability of the right ARV regimen and now take HTS to the people at their
the inability to assessing ARV at the right localities especially on “Lockdown-free
time could both contribute to a rapid Days” when the people can have a bit of
increase in the HIV plasma viremia of movement. Because of the economic
PLWH. This could also lead to the hardships now created by the COVID-19
development of HIV drug resistance by the Pandemic, people now consider it a priority
HIV RNA because of inadequate, to looking after themselves and their family
intermittent, or suboptimal drug exposure. sustenance first before considering any
In addition, the inability to assessing HIV other thing. We must now endeavor to
Testing Services (HTS) at the right time taking HTS to people at their business and
could spell a phase for the rapid spread of work places, offering and rendering them
HIV. The COVID-19 Pandemic has grossly our services once they are obliged. We need
hampered logistics for the shipment and to now prioritize high-risk groups, and map
movements of Public Health Commodities. out strategies to reaching them in clusters.
[25]
HIV services and logistics has been This continued effort will enable us to
generally slowed down with many keeping the pace with the first UNAIDS 90
deleterious effects already hovering if we do target.
not redouble our efforts at reprogramming 6.2 Access to ART
and strategizing our approaches. Efforts should now be intensified at
6. Reprogramming HIV Services during differentiating PLWH into different Models
the COVID-19 Pandemic of Care. Dispensing of ARVs at Community
Public Health efforts in HIV services Pharmacy Stores should be intensified. In
needs to be re-doubled, and a re-strategizing addition, the Multi-months Dispensing
in HIV Programming is now needed in (MMD) of ARVs should be rapidly
order to maintaining the gains already made encouraged. All newly diagnosed HIV
in HIV care and services. As different Positive clients should be encouraged to
countries begins to ease the COVID-19 commence treatment immediately. Efforts
Pandemic lockdowns, one obvious facts is should be made at ensuring the ready
that things may not go back to the way they availability of ARVs, as shortages or
were until a lasting cure or treatment is unavailability may lead to undue rationing
found for the SARS-CoV-2 infection. With which may not be convenient for the
the active spread of COVID-19 and the patients. Regular Health Talks during Clinic
major collapse of world economies, we visits should emphasise the importance of
must not lose our grip on the major gains taking ARV regimens as prescribed and
made in the fight against the HIV Pandemic. without fail. The danger associated with
Our strategies must be built around the poor adherence should also be emphasized.
UNAIDS 90:90:90 targets; hence, in our bid Ensuring a free flow of access to ARVs by
to maintaining the speed and momentum we PLWH and strict adherence to ARV
have gained in HIV Programming, we must regimens will help in keeping pace with the
urgently intensify our efforts on the second UNAIDS 90 target.
following: 6.3 Community Phlebotomy
6.1 Community HTS Outreaches Provisions should now be made at
In light of the restrictions on bleeding PLWH who are eligible for viral
movement occasioned by the COVID-19 load testing at the community level. Clusters
Pandemic, more Community Outreaches in of PLWH living in proximate communities
smaller units now needs to be organized on can be tracked and mapped into groups for
a regular basis. Large-scale outreaches collective ARV refills and HIV viral load
should be avoided in order to maintaining Phlebotomy. The use of Dried Blood Spot
Social Distancing. Since the people can no (DBS) for HIV viral load can greatly help
longer move freely and at will, we must simplify this effort. This effort will help
International Journal of Science and Healthcare Research (www.ijshr.com) 352
Vol.5; Issue: 2; April-June 2020Adeniyi David Segun et.al. HIV and COVID-19 comorbidity: current evidence
reduce the challenge of transportation and 7. CONCLUSION
restrictions placed on movement by The emergence of the COVID-19 pandemic
governments because of the COVID-19 in early December 2019 at Wuhan, China,
Pandemic. Moreover, for some PLWH who has so far changed some fundamental tenets
are afraid of visiting the hospitals because of the global order, as we know it. Massive
of the possible comorbidity risk associated global economic down turns, loss of jobs
with HIV and COVID-19, and the and sources of livelihoods, changes in social
possibility of having hospital contact with structures and a redefining of norms and
COVID-19 patients, having their viral load social exchanges. [27,28] Several chronic
samples taken at the community will come diseases conditions increase the risk, case
as a great relief. This effort when properly fatality, and mortality rate of the COVID-19
harnessed could help in maintaining the infection. In the midst of the hardships and
gains made at meeting the UNAIDS third 90 mental stress caused by this pandemic,
target. chronic diseases such as hypertension,
6.4 Enhance Adherence Counselling diabetes, COPDs, Cardiovascular diseases,
(EAC) and Cerebrovascular diseases all increases
The essence of carrying out HIV the chances of a case fatality with SARS-
viral load testing for PLWH is to assessing CoV-2 infection. [3,5,8] Studies have however
the efficacy of a given ARV regimen and to shown that with a normal CD4 T-helper
monitoring HIV viral load suppression. The cells count (>200 cells/µl), and with active
WHO has defined HIV viral load ARV regimen with no underlying chronic
suppression as an HIV patient having a health conditions, PLWH have similar
circulating HIV RNA of 1000 SARS-CoV-2.Thus, HIV infection
copies/ml. [26] PLWH with unsuppressed comorbidity with COVID-19 does not
HIV viral load are to be immediately predispose PLWH to additional risk,
tracked and enrolled into the EAC program. provided the HIV viral load is suppressed
A mandatory HIV viral load re-testing is to (200 cell/µl). [12] Several
program in order to assessing the un- drugs are undergoing trials as treatment
suppression to know whether it is because options against the COVID-19, however,
of non-adherence or because of ARVs Hydroxychloroquine with or without
failure. The outcome of the EAC should Azithromycin, Chloroquine, and
determine the next course of action for such Lopinavir/Ritonavir have all been proven
a client. not to be effective against the SARS-CoV-2
6.5 Community Support Group infection. [12, 20, 22] Some of these drugs have
Member also shown a deleterious adverse effect on
The HIV Community Support Group patients in randomized control trials. Two
Members (CSGMs) plays a pivotal role in drugs, Remdesivir and Famotidine are
helping to mobilize PLWH in the currently been tested for their promising
communities for HIV care and services. efficacy at increasing the survival chances
This experienced and specialized PLWH of COVID-19 patients. [12,22] In addition, a
should be involved in Community Tracking, dysregulated immune response to COVID-
ARV mobilization for PLWH in the 19 infection seen in PLWH might possibly
communities, and mobilization for viral load be conferring some level of protection
sampling. As informed members of PLWH against the SARS-CoV-2 infection in
in the communities, the CSGMs should PLWH. [18-19]
serve as the voice and eye of the HIV A lot has changed in the HIV care
programs at the community level. services because of the COVID-19
International Journal of Science and Healthcare Research (www.ijshr.com) 353
Vol.5; Issue: 2; April-June 2020Adeniyi David Segun et.al. HIV and COVID-19 comorbidity: current evidence
pandemic; nevertheless, a redoubling of International Journal of Infectious Diseases;
efforts is needed to maintaining the gains so Volume 94, May 2020, Pp. 91 -95
far made in HIV Care Services globally. 9. Yang, X.; Yu, Y.; and Xu, J. (2020).
New HIV programming strategies now need Clinical Course and Outcome of Critically
to be devised at reaching PLWH at the Ill Patients with SARS-CoV-2 Pneumonia
in Wuhan, China: a Single Centered
community level and at testing HIV exposed Retrospective, Observational Study. Lancet
populations. Achieving the UNAIDS Respir Med; 2000. Doi: 10.1016/s2213-
90:90:90 targets is a mandate and 2600(20)30079-5
maintaining the pace and momentum 10. Richardson, S.; Hirsch, J.S.; Narasimhan,
already achieved in HIV care and services M. et al. (2020). Presenting Characteristics,
will help in improving current efforts aimed Comorbidities, and Outcomes Among 5700
at integrating the COVID-19 services into Patients Hospitalized with COVID-19 in the
the already existing HIV care services New York City Area. JAMA; 323(20): Pp.
platforms. 2052 – 2059
11. UNAIDS (2020). Joint United Nations
REFERENCES Program on HIV/AIDS, Geneva 2020.
1. Ducharme, J. (2020). World Health Retrieved from:
Organization Declares COVID-19 a unaids.org/sites/default/files/media_asset/20
‘Pandemic’: Here is What That Means. 19-UNAIDS-data_en.pdfn
Retrieved from: time.com/5791661/who- 12. British HIV Association [BHIVA] (2020).
coronavirus-pandemic-declaration/ BHIVA, DAIG, EACS, GESIDA and Polish
2. John Hopkins University [JHU] (2020). Scientific AIDS Society Statement on Risk
COVID-19 Case Tracker. Retrieved from: of COVID-19 for People Living with HIV
coronavirus.jhu.edu (PLWH). Retrieved from:
3. Wang, B.; Li, R.; Lu, Z. et al. (2020). Does bhiva.org/BHIVA-DAIG-EACS-GESIDA-
Comorbidities Increase the Risk of Patients Polish-Sceintific-AIDS-Society-Statement-
with COVID-19: Evidence from Meta- on-risk-of-COVID-19-for-PLWH
Analysis. Aging; 12(7): Pp. 6049-6057 13. Joob, B. and Wiwanitkit, V. (2020). SARS-
4. Liu, W.; Tao, Z.W.; Wang, L. et al. (2020). CoV-2 and HIV. J Med Virol. [Epub ahead
Analysis of Factors Associated with Disease of print]. Retrieved from: doi:
Outcomes in Hospitalized Patients with 10.1002/jmv.25782
2019 Novel Coronavirus Disease. Chinese 14. Blanco, J.L.; Ambrosioni, J.; Garcia, F. et
Medical Journal; Volume 133, Issue 9, Pp. al. (2020). COVID-19 in Patients with HIV:
1032 – 1038 Clinical Case Series. The Lancet HIV;
5. Clerkin, K.J.; Fried, J.A.; Raikhelkar, J. et Volume 7, Issue 5, Pp. E314-E316
al. (2020). COVID-19 and Cardiovascular 15. Haerter, G.; Spinner, C.D.; Roider, J. et al.
Disease. Circulation; 2020; 141: Pp. 1648 – (2020). COVID-19 in People Living with
1655 Human Immunodeficiency Virus: a Case
6. Li, B.; Yang, J.; Zhao, F. et al. (2020). Series of 33 Patients. Springer – Verlag
Prevalence and Impact of Cardiovascular GmbH, Germany. Retrieved from:
Metabolic Diseases on COVID-19 in China. dio.org/10.1007/s15010-020-01438-z
Clinical Research in Cardiology; Volume 16. Emami, A.; Javanmardi, F.; Pirbonyeh, N. et
109, Pp. 531 – 538 al. (2020). Prevalence of Underlying
7. Wang, D.; Hu, B.; Hu, C. et al. (2020). Diseases in Hospitalized Patients with
Clinical Characteristics of 138 Hospitalized COVID-19: a Systematic Review and Meta-
Patients with 2019 Novel Coronavirus- Analysis. Arch Acad Emerg Med; 8(1): Pp.
infected Pneumonia in Wuhan, China. e35
JAMA; 323(11): Pp. 1061 – 1069 17. Pal, R. and Bhansali, A. (2020). COVID-19,
8. Yang, J.; Zheng, Y.; Gou, X. et al. (2020). Diabetes Mellitus and ACE2: The
Prevalence of Comorbidities and its Effects Conundrum. Diabetes Research and Clinical
in Patients Infected with SARS-CoV-2: a Practice; Volume 162, 108135. Doi:
Systematic Review and Meta-Analysis. 10.1016/j.diabres.2020.108132
18. Guo, W.; Ming, F.; Dong, Y. et al. (2020).
A Survey for COVID-19 among HIV/AIDS
International Journal of Science and Healthcare Research (www.ijshr.com) 354
Vol.5; Issue: 2; April-June 2020Adeniyi David Segun et.al. HIV and COVID-19 comorbidity: current evidence
Patients in two Districts of Wuhan, China. 19 Pandemic. The Lancet HIV; Volume 7,
Preprints with the Lancet – Retrieved from: Issue 5, Pp. E308-E309
papers.ssrn.com/sol3/papers.cfm?abstract_i 25. UNICEF (2020). COVID-19 Impact
d=3550029 Assessment on Supplies and Logistics
19. Zhao, J.; Liao, X.; Wang, H. et al. (2020). Sourced by UNICEF Supply Division.
Early Virus Clearance and Delayed Retrieved from:
Antibody Response in a Case of unicef.org/supply/stories/covid-19-impact-
Coronavirus Disease 2019 (COVID-19) assessment-supplies-and-logistics-sourced-
with a History of Coinfection with Human unicef-supply-division
Immunodeficiency Virus Type 1 and 26. WHO (2013). Consolidated Guidelines on
Hepatitis C virus. Clinical Infectious the use of antiretroviral drugs for treatment
Diseases, ciaa408, and preventing HIV infection:
https://doi.org/10.1093/cid/ciaa408 Recommendations for a Public Health
20. Zhu, F.; Cao, Y.; and Zhou, M. (2020). Approach. Retrieved from:
Reply to Comments on Co-infection of who.int/iris/bitstream/10665/85321/1/97892
SARS-CoV-2 and HIV in a Patient in 41505727_eng.pdf
Wuhan City, China. Journal of Medical 27. Sergio, C.; Stephan, L.; and Emil, V.
Virology; doi: 10.1002/jmv.25838 (2020). Pandemics Depress the Economy
21. Kupferschmidt, K. and Cohen, J. (2020). Public Health Interventions Do Not:
Race to find COVID-19 treatments Evidence from the 1918 Flu. Retrieved
accelerates. Science; Volume 367, Issue from:
6485, Pp. 1412 – 1413 papers.ssrn.com/sol3/papers.cfm?abstract_i
22. CDC (2020). Information for Clinicians on d=3561560
Investigational Therapeutics for Patients 28. Akinleye, O.; Dauda, S.; Oladoyin, R. et al.
with COVID-19. Retrieved from: (2020). Impact of COVID-19 Pandemic on
cdc.gov/coronavirus/2019- Financial Health and Food Security: a
ncov/hcp/therapeutic-options.html Survey-Based Analysis. Retrieved from:
23. Adepoju, P. (2020). Tuberculosis and HIV papers.ssrn.com/sol3/papers.cfm?abstract_i
Responses Threatened by COVID-19. The d=3619245
Lancet HIV; Volume 7, Issue 5, Pp. E319-
E320 How to cite this article: Segun AD. HIV and
24. Jiang, H.; Zhou, Y.; and Tang, W. (2020). COVID-19 comorbidity: current evidence.
Maintaining HIV Care during the COVID- International Journal of Science & Healthcare
Research. 2020; 5(2): 349-355.
******
International Journal of Science and Healthcare Research (www.ijshr.com) 355
Vol.5; Issue: 2; April-June 2020You can also read
